IP Library › Granted Patent US 11,304,974
Granted Patent B2
US 11,304,974 · App. 16/489,207 · Granted Apr 19, 2022

Nanosystems comprising silver and antibiotics and their use for the treatment of bacterial infections

Inventor: Luis Jesús Lostao Camón (Saragossa, ES)
Assignee: LABORATORIOS ENOSAN, S.L.
A61K33/38A61K9/0053A61K9/08A61K9/14A61K38/14A61K47/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,304,974
App. No.
16/489,207
Granted
Apr 19, 2022
Kind
B2
Abstract

A composition including metallic silver nanoparticles is supported on a carrier, wherein the carrier is in the form of particles. The carrier is selected from an inert carrier or an antibiotic. The composition further includes at least one antibiotic in the case the carrier is an inert carrier. A related nanosystem includes a composition having metallic silver nanoparticles or a mixture of silver nanoparticles and at least one antibiotic for use in the treatment of an infection caused by at least one strain of bacteria resistant to at least one antibiotic. Pharmaceutical compositions and methods for the preparation of these compositions and nanosystems are also used for the treatment of bacterial infections.

Claims (21)

1. A composition, comprising metallic silver nanoparticles supported on a carrier, the carrier being in the form of particles, wherein the carrier is an antibiotic.

2. The composition according to claim 1 , the particles having a mean diameter between 0.1 and 200 micrometers.

3. The composition according to claim 1 , wherein the antibiotic is selected from penicillins, cephalosporins, monobactams, beta lactamase inhibitors, carbapenems, aminoglucosides, quinolones, tetracyclines, glicopeptides, colistin, sulfamethoxazole/trimethoprim, fosfomycin, nitrofurantoin, chloramphenicol, clindamycin, fusidic acid, linezolid, mupirocin, daptomycin, clindamycin and rifampicin.

4. The composition according to claim 1 , wherein the weight ratio of silver with respect to the total amount of antibiotics is between 10:100 and 0.1:100.

5. The composition according to claim 1 , wherein the mean particle size of the metallic silver nanoparticles is comprised between 1 and 100 nanometers.

6. A nanosystem comprising a composition according to claim 1 or a mixture of silver nanoparticles and at least one antibiotic, for use in the treatment of an infection caused by at least one strain of bacteria resistant to at least one antibiotic.

7. The nanosystem according to claim 6 , wherein the infection is caused by at least one strain of gram negative bacteria, resistant to at least one antibiotic.

8. The nanosystem according to claim 6 , which comprises a mixture of silver nanoparticles and an antibiotic, wherein the antibiotic is selected from penicillins, cephalosporins, monobactams, beta lactamase inhibitors, carbapenems, aminoglucosides, quinolones, tetracyclines, glicopeptides, colistin, sulfamethoxazole/trimethoprim, fosfomycin, nitrofurantoin, chloramphenicol, clindamycin, fusidic acid, linezolid, mupirocin, daptomycin, clindamycin and rifampicin.

9. The nanosystem according to claim 8 , comprising colloidal silver nanoparticles and at least one antibiotic, for use in the treatment of an infection caused by at least one strain of bacteria resistant to at least one antibiotic.

10. The nanosystem according to claim 8 , wherein the silver nanoparticles are used in a weight ratio with respect to the total amount of antibiotics between 1:100 and 0.1:100.

11. A preparation process of a composition according to claim 1 , the process including the following steps:

a) preparing a dissolution of a silver ion;

b) adding said silver ion dissolution to a carrier in the form of particles, wherein the carrier is an antibiotic; and

c) adding a reducing agent to the mixture obtained in b), to obtain metallic silver supported on said carrier.

12. A pharmaceutical composition which comprises at least one pharmaceutically acceptable excipient and a composition according to claim 1 , for use as a medicament.

13. A pharmaceutical composition which comprises at least one pharmaceutically acceptable excipient and a composition according to claim 1 , for use in the treatment of an infection.

14. A pharmaceutical composition which comprises at least one pharmaceutically acceptable excipient and a composition according to claim 1 , for oral use in the treatment of an infection.

15. The composition according to claim 1 , wherein the mean particle size of the metallic silver nanoparticles is comprised between 10 and 90 nanometers.

16. The composition according to claim 1 , wherein the mean particle size of the metallic silver nanoparticles is comprised between 10 and 70 nanometers.

17. The composition according to claim 1 , wherein the mean particle size of the metallic silver nanoparticles is comprised between 10 and 50 nanometers.

18. The composition according to claim 1 , wherein the mean particle size of the metallic silver nanoparticles is comprised between 20 and 30 nanometers.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2022
From: LOSTAO CAMÓN, LUIS JESÚS
To: LABORATORIOS ENOSAN, S.L.
Reel/Frame 058837/0524 →
Priority Claims (1)
EP 17382196 · Apr 10, 2017 · regional
Continuity (1)
Related Publication 20200330509A1 · Oct 22, 2020
Cited By (1)
US 12,303,546